Early Diagnostic Marker for Nasopharyngeal Carcinoma: A Study Based on Serum Proteomics Screening and ELISA Validation

ABSTRACT: This study focuses on the critical challenge of early NPC detection, underscored by the observation that only 15.8% of newly diagnosed cases were identified at an early stage in our institution between 2019 and 2020. Current screening methods, especially those relying on EBV antibody detection, demonstrate suboptimal sensitivity and low positive predictive value. These limitations not only cause unnecessary psychological distress in healthy individuals but also lead to the inefficient allocation of healthcare resources. Consequently, improving the sensitivity and positive predictive value of early NPC screening is of utmost clinical significance. We propose an innovative methodological framework that integrates state-of-the-art mass spectrometry and proteomic technologies for the systematic identification of potential serum biomarkers in NPC. Our approach incorporates the "Blood+" detection platform, which synergistically combines Field Asymmetric Ion Mobility Spectrometry (FAIMS) with advanced machine learning algorithms, thereby enhancing both detection sensitivity and analytical reliability for large-scale sample processing. The research methodology was structured into three sequential phases: (1) initial biomarker discovery using high-throughput small-sample screening techniques, (2) preliminary validation via small-scale ELISA analysis, and (3) comprehensive confirmation through large-scale ELISA validation. This systematic investigation is expected to provide robust data to support NPC screening initiatives with the potential to improve early detection accuracy, reduce false-positive rates associated with EBV antibody testing, alleviate patient psychological distress, and optimize clinical outcomes.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Blood Serum

DISEASE(S): Nasopharynx Carcinoma

SUBMITTER: Yueying Wang  

LAB HEAD: Yueying Wang

PROVIDER: PXD077783 | Pride | 2026-09-21

REPOSITORIES: Pride